NEW YORK, Sept. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
Summary GlobalData has released its new Country report, "PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022". Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
The DES market in China is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver in this market will be the launch of Diquas and CF101 and generally increased access to medical care for China's enormous population.
- Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in China from 2012-2022. - Analysis of the impact of key events as well the drivers and restraints affecting China DES market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for DES - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2012-2022 in China.1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Related Reports 83 Disease Overview 103.1 Etiology and Pathophysiology 103.1.1 Etiology 103.1.2 Pathophysiology 123.1.3 Classification 143.1.4 Prognosis 143.1.5 Quality of Life 153.2 Symptoms 154 Disease Management 174.1 Overview 174.1.1 Diagnosis Overview 174.1.2 Treatment Guidelines 194.1.3 Treatment Overview 244.2 China 274.2.1 Diagnosis 274.2.2 Clinical Practice 275 Competitive Assessment 285.1 Overview 285.2 Strategic Competitor Assessment 285.3 Product Profiles – Major Brands 305.3.1 Diquas (diquafosol tetrasodium) 305.3.2 Additional Therapies 336 Opportunity and Unmet Need 376.1 Overview 376.2 Diagnostic tests are not specific enough to identify subgroups of patients 386.3 Frequent dosing and side effects limit compliance 396.4 Lack of physician and patient awareness 406.5 Trial design may be a factor in so few drugs being approved 416.6 Unmet Needs Gap Analysis 426.7 Comprehensive method for measuring dry eye signs and severity levels 436.8 Increase treatment rates among milder forms of the disease 447 Pipeline Assessment 457.1 Overview 457.2 Promising drugs in clinical development 467.2.1 CF-101 478 Market Outlook 518.1 China 518.1.1 Forecast 518.1.2 Key Events 538.1.3 Drivers and Barriers 539 Appendix 559.1 Bibliography 559.2 Abbreviations 589.3 Methodology 609.4 Forecasting Methodology 609.4.1 Diagnosed DES patients 609.4.2 Percent Drug-treated Patients 619.4.3 Drugs Included in Each Therapeutic Class 619.4.4 General Pricing Assumptions 619.4.5 Individual Drug Assumptions 629.4.6 Generic Erosion 639.5 Physicians and Specialists Included in this Study 649.6 About the Authors 659.6.1 Author 659.6.2 Global Head of Healthcare 669.7 About GlobalData 679.8 Contact Us 679.9 Disclaimer 67
1.1 List of Tables Table 1: Symptoms of Dry Eye Syndrome 16
Table 2: Treatment Guidelines for Dry Eye Syndrome 24
Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 26
Table 4: Leading Treatments for Dry Eye Syndrome, 2012 29
Table 5: Product Profile – Diquas 31
Table 6: Diquas SWOT Analysis, 2012 33
Table 7: Summary of Minor Drug Classes, 2012 36
Table 8: Overall Unmet Needs – Current Level of Attainment 38
Table 9: Clinical Unmet Needs – Gap Analysis, 2012 43
Table 10: Dry Eye Syndrome – Phase Pipeline, 2012 46
Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 47
Table 12: Product Profile – CF101 48
Table 13: CF101 SWOT Analysis, 2012 50
Table 14: Sales Forecasts ($m) for Dry Eye Syndrome in China, 2012–2022 52
Table 15: Key Events Impacting Sales for Dry Eye Syndrome China, 2012–2022 53
Table 16: China, Dry Eye Syndrome Market – Drivers and Barriers, 2012–2022 53
1.2 List of Figures
Figure 1: Dry Eye Syndrome – Disease Etiology 11Figure 2: Tear Film in Normal Eye and Dry Eye 12Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 17Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006 20Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006 21Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007 22Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011 23Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022 46Figure 9: Sales for Dry Eye Syndrome in China by Drug Class, 2012–2022 52
To order this report: PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022 http://www.reportlinker.com/p01622994/PharmaPoint-Dry-Eye-Syndrome---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Contact Clare: email@example.com
US:(339) 368 6001
Intl:+1 339 368 6001
Copyright©2012 PR Newswire.
All rights reserved